Skip to content
The Policy VaultThe Policy Vault

Afinitor DisperzCareFirst (Caremark)

TSC-associated partial-onset seizures

Initial criteria

  • Used for treatment of TSC or its associated manifestations

Reauthorization criteria

  • Continuation may be approved when no unacceptable toxicity or disease progression

Approval duration

12 months